Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
235 Clinical Trials near Montvale, NJ
Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerIO102/IO103 + Nivolumab-Relatlimab for Melanoma
Montvale, New Jersey
This trial is testing new vaccines combined with two existing drugs to treat people with melanoma that can't be surgically removed and who haven't received any treatment yet. The vaccines aim to help the body recognize and attack cancer cells, while the drugs enhance the immune system's ability to fight the cancer. One of the drugs has been shown to greatly improve survival in widespread, inoperable malignant melanoma.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Uveal Melanoma, CNS Metastases, Others
Must Not Be Taking:Steroids, Immunosuppressants, Live Vaccines
43 Participants Needed
Immunotherapy +/− Targeted Therapy for Nasopharyngeal Cancer
Montvale, New Jersey
This phase II trial tests how well nivolumab and ipilimumab immunotherapy with or without cabozantinib works in treating patients with nasopharyngeal cancer that has come back (after a period of improvement) (recurrent), has spread from where it first started (primary site) to other places in the body (metastatic), or for which no treatment is currently available (incurable). Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Giving immunotherapy with nivolumab and ipilimumab and targeted therapy with cabozantinib may help shrink and stabilize nasopharyngeal cancer.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Autoimmune Diseases, Active Tumor Bleeding, Others
Must Not Be Taking:Anticoagulants, Immunosuppressants
50 Participants Needed
Tucatinib for Metastatic Breast Cancer
Montvale, New Jersey
The purpose of this study to see how the brain absorbs, distributes, and gets rid of tucatinib in people who have HER2+ cancers (breast cancer, NSCLC, CRC, or GEC) that have spread to the brain, and to learn more about how cancer cells develop resistance to treatment. The researchers will do research tests to look for genetic differences between HER2+ breast cancer that has spread to the brain and progressed during treatment with tucatinib and cancers that are being treated with tucatinib for the first time.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Sex:Female
Key Eligibility Criteria
Disqualifiers:Allergy To Tucatinib, Significant Comorbidities, Others
Must Not Be Taking:CYP2C8 Inhibitors, CYP3A4 Inducers
28 Participants Needed
ML-004 for Autism
Orangeburg, New York
This trial is testing the safety of a treatment called ML-004 in adolescents and adults with Autism Spectrum Disorder (ASD). The main goal is to ensure that the treatment does not cause any harmful side effects.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 2
Age:12 - 46
Key Eligibility Criteria
Disqualifiers:Rett Syndrome, Epilepsy, Hypertension, Others
120 Participants Needed
Immunotherapy for Hodgkin's Lymphoma
Montvale, New Jersey
This trial is testing a new treatment called mosunetuzumab against the usual treatment, rituximab, for patients with a type of cancer called NLPHL. Both treatments help the immune system find and kill cancer cells by targeting a specific protein on these cells. The goal is to see if mosunetuzumab can improve survival better than rituximab.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Classical Hodgkin Lymphoma, CNS Involvement, Others
Must Not Be Taking:Immunosuppressants, Investigational Agents
70 Participants Needed
Cord Blood Transplant for Blood Cancers
Montvale, New Jersey
Cord blood transplants (CBT) are a standard treatment for adults with blood cancers. MSK has developed a standard ("optimized") practice for cord blood transplant (CBT). This optimized practice includes how patients are evaluated for transplant, the conditioning treatment (standard chemotherapy and total body irradiation therapy) given to prepare the body for transplant, the amount of stem cells transplanted, and how patients are followed during and after transplant.The purpose of this study is to collect information about participant outcomes after CBT following MSK's optimized practice. The researchers will look at outcomes of the CBT treatment such as side effects, disease relapse, GVHD, and immune system recovery after CBT treatment.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:21 - 65
Key Eligibility Criteria
Disqualifiers:Myelofibrosis, CNS Disease, HIV, Others
Must Not Be Taking:Checkpoint Inhibitors
54 Participants Needed
Isatuximab for Immune Cytopenia After Stem Cell Transplant
Montvale, New Jersey
The purpose of this study is to find out whether isatuximab is an effective treatment for people who developed immune cytopenias/ICs after allogeneic hematopoietic cell transplant/allo-HCT.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Relapse, Thrombotic Microangiopathy, HIV, Others
Must Be Taking:Corticosteroids, IVIG, Rituximab
25 Participants Needed
Enfortumab Vedotin for Bladder Cancer
Montvale, New Jersey
This trial is testing enfortumab vedotin, a drug that targets and kills cancer cells, in patients with upper urinary tract urothelial carcinoma who can't or won't use cisplatin and are planning surgery. Enfortumab vedotin is a new type of drug that targets a specific protein on cancer cells and delivers a substance that kills these cells.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Metastatic Disease, Uncontrolled Diabetes, Heart Failure, Others
Must Be Taking:HAART Therapy
24 Participants Needed
Erdafitinib for Brain Cancer
Montvale, New Jersey
This phase II trial tests how well erdafitinib works in controlling IDH-wild type (WT), FGFR-TACC gene fusion positive gliomas that have come back after a period of improvement (recurrent) or that are growing, spreading, or getting worse (progressive). Erdafitinib is in a class of medications called kinase inhibitors. It works by blocking the action of an abnormal FGFR protein that signals tumor cells to multiply. This may help keep tumor cells from growing and may kill them. Giving erdafitinib may help to slow the growth of, or to shrink, tumor cells in patients with recurrent or progressive IDH-wild type gliomas with FGFR-TACC gene fusion.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Pregnancy, Uncontrolled Illness, FGFR Inhibitors, Others
Must Not Be Taking:CYP2C9 Inducers, CYP3A4 Inducers
35 Participants Needed
NALIRIFOX + Radiation for Pancreatic Cancer
Montvale, New Jersey
The researchers are doing this study to find out whether using the chemotherapy regimen NALIRIFOX in combination with ablative dose radiation therapy (AD-XRT) and the standard chemotherapy drug capecitabine is an effective treatment approach for people with locally advanced or borderline resectable pancreatic ductal adenocarcinoma (PDAC) before surgery. This type of treatment approach is called total neoadjuvant therapy (TNT). The researchers will also look at whether the sequence of the treatment approach (NALIRIFOX + ADXRT and capecitabine followed by surgery, when it is possible) is effective and causes few or mild side effects in participants. An important purpose of the study is to see how the study treatment (NALIRIFOX + AD-XRT and capecitabine) affects participants' quality of life. The researchers will measure quality of life by having participants fill out questionnaires
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Metastatic Cancer, Major Surgery, Neuropathy, Others
60 Participants Needed
Exercise for Colorectal Cancer Side Effects
Montvale, New Jersey
The purpose of this study is to find the level of aerobic exercise (AT) that is practical, is safe, and has positive effects on the body that may reduce the side effects of therapy. The study will also look at the way the body responds to exercise and whether there are differences in treatment. This will include looking at the highest treatment dose participants receive, how many people stop, delay, or reduce the treatment, and whether additional medication is needed to treat side effects of therapy.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Other Cancer, Metastatic Malignancy, Others
216 Participants Needed
Pre-Transplant Inflammation Treatment for Immune System Disorders
Montvale, New Jersey
The researchers are doing this study to find out whether emapalumab or a combination of fludarabine and dexamethasone are effective in preparing people with a primary immune regulatory disorder (PIRD) and/or an autoinflammatory condition to receive a stem cell transplant. The researchers will look at how well the study treatments reduce inflammation and aid in the engraftment process (the process of donated stem cells traveling to the bone marrow, where they begin to make new immune cells.
"Funding Source - FDA OOPD"
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Uncontrolled Infection, Previous Allo-HCT, HIV/HTLV, Pregnancy, Others
39 Participants Needed
Avutometinib + Defactinib for Endometrial Cancer
Montvale, New Jersey
This study will test if Avutometinib (VS-6766) in combination with Defactinib is an effective treatment for advanced or recurrent mesonephric gynecologic cancer.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Sex:Female
Key Eligibility Criteria
Disqualifiers:Localized Disease, MEK Inhibitor, Others
Must Not Be Taking:Warfarin, Strong CYP3A4, Others
40 Participants Needed
Exercise Therapy for Prostate Cancer
Montvale, New Jersey
This trial is studying how regular walking exercises at home affect people with low-risk prostate cancer who are being monitored but not actively treated. Participants will either follow a specific walking routine or continue their usual exercise habits. Researchers aim to see if the walking routine has any impact on prostate cancer indicators.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Sex:Male
Key Eligibility Criteria
Disqualifiers:Metastatic Malignancy, Anticancer Therapy, Others
36 Participants Needed
Immune Suppression Treatment for Sickle Cell Disease
Montvale, New Jersey
Hematopoietic Cell Transplantation/HCT involves receiving healthy blood-forming cells (stem cells) from a donor to replace the diseased or damaged cells in participants' bone marrow. The researchers think giving participants treatment with fludarabine and dexamethasone, drugs that lower the activity of the body's immune system (immune suppression), before standard conditioning therapy and HCT may help prevent serious side effects, including graft failure and GvHD. In this study, depending on how participants' body responds to the fludarabine and dexamethasone, the study doctor may decide participants should receive another drug, called cyclophosphamide, instead of fludarabine. In addition, depending on the results of participants' routine blood tests, participants may receive the drugs bortezomib and rituximab, which also help with immune suppression.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:2 - 50
Key Eligibility Criteria
Disqualifiers:HIV, Active Hepatitis B Or C, Others
24 Participants Needed
Aerobic Exercise for Breast Cancer
Montvale, New Jersey
This trial compares two types of walking exercises: one with a fixed routine and one that changes based on how participants respond. The goal is to see which method better improves heart and lung fitness. Participants are people who can benefit from regular walking exercises.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Sex:Female
Key Eligibility Criteria
Disqualifiers:Other Cancer, Metastatic Malignancy, Mental Impairment, Others
140 Participants Needed
Photobiomodulation Therapy for Oral Graft-Versus-Host Disease
Montvale, New Jersey
The purpose of this study is to find out whether photobiomodulation/PBM therapy using the Thor LX2.3 therapy system is a safe and effective treatment for oral Graft-Versus-Host Disease/GVHD.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:4+
Key Eligibility Criteria
Disqualifiers:Uncontrolled Infection, Head/neck Cancer, Pregnant, Others
44 Participants Needed
Darolutamide for Salivary Gland Cancer
Montvale, New Jersey
This phase II trial tests how well darolutamide and leuprolide acetate work in treating patients with androgen receptor positive salivary cancer that has spread from where it first started (primary site) to other places in the body (metastatic), cannot be removed by surgery (unresectable) or that has come back after a period of responding to prior therapy (recurrent). Darolutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of cancer cells. Leuprolide acetate is in a class of medications called gonadotropin-releasing hormone (GnRH) agonists. It works by decreasing the amount of certain hormones in the body. Giving darolutamide in combination with leuprolide acetate may help to stop the growth of tumor cells that need androgens to grow or shrink them.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Vascular Events, Allergic Reactions, Others
Must Be Taking:Androgen Inhibitors, GnRH Agonists
21 Participants Needed
Sucralfate for Esophagitis
Montvale, New Jersey
This trial is testing sucralfate, a medication that protects the esophagus, to see if it can prevent or reduce symptoms of radiation esophagitis. The study focuses on patients undergoing radiation therapy who are at risk of developing this painful condition. Sucralfate works by coating the esophagus to shield it from damage. Sucralfate has been evaluated for its protective adherence to denuded surfaces and bile salt-binding properties, showing efficacy in treating reflux esophagitis.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:PEG Tube, Opioid Use Disorder, Others
Must Not Be Taking:Opioids
142 Participants Needed
Targeted Radiation + Drug Therapy for Lung Cancer
Montvale, New Jersey
The purpose of this study is to see whether adding liver stereotactic ablative radiotherapy/L-SABR to standard drug therapy is better than standard drug therapy alone for people with metastatic non-small cell lung cancer/NSCLC.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Active Hepatitis B, Hepatitis C, Immunosuppression, Autoimmune Disease, Others
Must Be Taking:Anti-PD-(L)1, Platinum Chemotherapy
68 Participants Needed
Why Other Patients Applied
"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."
IZ
Healthy Volunteer PatientAge: 38
"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."
HZ
Arthritis PatientAge: 78
"I've been struggling with ADHD and anxiety since I was 9 years old. I'm currently 30. I really don't like how numb the medications make me feel. And especially now, that I've lost my grandma and my aunt 8 days apart, my anxiety has been even worse. So I'm trying to find something new."
FF
ADHD PatientAge: 31
"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."
ID
Pancreatic Cancer PatientAge: 40
"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."
AG
Paralysis PatientAge: 50
Pertzye for Pancreatic Cancer
Montvale, New Jersey
The main purpose of this study is to see how pancrelipase affects the body mass index (BMI) in people with metastatic PDAC. BMI is a measure based on a person's height and weight. Other study goals are to explore two different dosing schedules of pancrelipase and to evaluate pancrelipase in people who do not have symptoms of EPI.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Celiac Disease, Cystic Fibrosis, Chronic Pancreatitis, Others
17 Participants Needed
Tislelizumab + Chemotherapy for Lung Cancer
Montvale, New Jersey
The purpose of this study is to assess the antitumor activity, safety, and tolerability of tislelizumab plus investigational agent(s) with or without chemotherapy. This study is structured as a master protocol with separate sub- studies. Sub-study 1 includes participants with non-small cell lung cancer (NSCLC) with high programmed cell death protein ligand-1 (PD-L1) expression (≥ 50%), and Sub-study 2 includes participants with NSCLC with low or negative (PD-L1) expression (\< 50%).
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Small Cell Lung Cancer, Actionable Mutations, Others
Must Not Be Taking:Chinese Herbal Medicines
400 Participants Needed
ZEN003694 for Squamous Cell Lung Cancer
Montvale, New Jersey
The purpose of this study is to find out whether ZEN003694 is an effective treatment for people with advanced squamous cell lung cancer with a mutation in the NSD3 gene.
ZEN003694 is a type of drug called a BET inhibitor. Researchers think ZEN003694 may help here because the drug works by blocking a group of proteins called bromodomain and extra-terminal (BET) proteins, which may counteract the effect of NSD3 on tumor growth. Blocking these proteins may slow or stop the growth of the cancer.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Cardiac Disease, Active Infections, Others
Must Not Be Taking:CYP3A4 Inducers, CYP1A2 Substrates, P-gp Inhibitors, Factor Xa/IIa Inhibitors
13 Participants Needed
Radiotherapy + Cemiplimab for Skin Cancer
Montvale, New Jersey
The purpose of the study is to see if the combination of radiation therapy and cemiplimab immunotherapy is an effective treatment for people with locally advanced, unresectable CSCC.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Autoimmune Disease, Hematopoietic Malignancy, Metastases, Others
Must Not Be Taking:Immunosuppressants, Antirheumatics, APD1, PI3Kδ
34 Participants Needed
SDX-7320 + Eribulin for Breast Cancer
Montvale, New Jersey
The researchers are doing this study to find out whether the study drug, SDX-7320, when combined with the standard chemotherapy eribulin, is an effective treatment for people with TNBC and metabolic dysfunction. The researchers will also look at whether the study treatment (SDX-7320 combined with eribulin) is safe and causes few or mild side effects in participants. The researchers will compare this treatment approach to eribulin alone.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Diabetes, CNS Pathology, Others
Must Not Be Taking:Antihyperglycemics, QT-prolonging Drugs
55 Participants Needed
Know someone looking for new options?
Spread the word